Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

redhill biopharma ltd. - RDHL

RDHL

Close Chg Chg %
0.81 -0.01 -1.68%

Closed Market

0.80

-0.01 (1.68%)

Volume: 12.91K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: redhill biopharma ltd. - RDHL

RDHL Key Data

Open

$0.81

 Day Range

0.79 - 0.82

52 Week Range

0.71 - 3.31

 Market Cap

$4.07M

Shares Outstanding

5.09M

 Public Float

4.53M

Beta

4.92

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$78.99

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

24.57K

  

RDHL Performance

1 Week
 
 6.59%
 
1 Month
 
 -13.11%
 
3 Months
 
 -22.39%
 
1 Year
 
 -59.01%
 
5 Years
 
 -99.99%
 

RDHL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About redhill biopharma ltd. - RDHL

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

RDHL At a Glance

RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv, Tel Aviv 6473921
Phone 972-3-541-3131 Revenue 8.08M
Industry Pharmaceuticals: Major Net Income -8,307,241.54
Sector Health Technology 2024 Sales Growth 24.074%
Fiscal Year-end 12 / 2025 Employees 35
View SEC Filings

RDHL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.947
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.29
Enterprise Value to Sales 0.42
Total Debt to Enterprise Value 0.105

RDHL Efficiency

Revenue/Employee 230,890.676
Income Per Employee -237,349.758
Receivables Turnover 2.813
Total Asset Turnover 0.393

RDHL Liquidity

Current Ratio 0.536
Quick Ratio 0.368
Cash Ratio 0.208

RDHL Profitability

Gross Margin 60.313
Operating Margin -152.356
Pretax Margin -102.797
Net Margin -102.797
Return on Assets -40.434
Return on Equity N/A
Return on Total Capital 191.986
Return on Invested Capital N/A

RDHL Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -8.227
Total Debt to Total Assets 1.973
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital -0.069
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Redhill Biopharma Ltd. - RDHL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
85.82M 61.56M 6.51M 8.08M
Sales Growth
+32.41% -28.27% -89.42% +24.07%
Cost of Goods Sold (COGS) incl D&A
49.44M 33.21M 3.45M 3.21M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
18.16M 8.12M 1.98M 621.94K
Depreciation
1.92M 2.13M 1.44M 590.79K
Amortization of Intangibles
16.25M 5.99M 543.60K 31.15K
COGS Growth
+33.08% -32.83% -89.61% -7.04%
Gross Income
36.38M 28.35M 3.06M 4.87M
Gross Income Growth
+31.51% -22.06% -89.20% +59.12%
Gross Profit Margin
+42.39% +46.06% +47.03% +60.31%
2021 2022 2023 2024 5-year trend
SG&A Expense
117.57M 71.03M 34.41M 17.19M
Research & Development
29.52M 7.25M 3.52M 1.60M
Other SG&A
88.05M 63.78M 30.90M 15.59M
SGA Growth
+28.08% -39.59% -51.55% -50.06%
Other Operating Expense
- - - -
-
Unusual Expense
- (13.37M) (21.53M) (4.39M)
EBIT after Unusual Expense
(81.19M) (29.31M) (9.82M) (7.92M)
Non Operating Income/Expense
(16.16M) (41.60M) 34.11M 142.67K
Non-Operating Interest Income
51.04K 139.45K 93.76K 133.63K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
460.32K 484.10K 426.90K 530.51K
Interest Expense Growth
-35.16% +5.17% -11.82% +24.27%
Gross Interest Expense
460.32K 484.10K 426.90K 530.51K
Interest Capitalized
- - - -
-
Pretax Income
(97.81M) (71.39M) 23.85M (8.31M)
Pretax Income Growth
-27.51% +27.01% +133.41% -134.82%
Pretax Margin
-113.98% -115.97% +366.25% -102.80%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(97.81M) (71.39M) 23.85M (8.31M)
Minority Interest Expense
- - - -
-
Net Income
(97.81M) (71.39M) 23.85M (8.31M)
Net Income Growth
-27.51% +27.01% +133.41% -134.82%
Net Margin Growth
-113.98% -115.97% +366.25% -102.80%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(97.81M) (71.39M) 23.85M (8.31M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(97.81M) (71.39M) 23.85M (8.31M)
EPS (Basic)
-2102.2538 -1152.7718 92.0622 -6.7318
EPS (Basic) Growth
+0.17% +45.16% +107.99% -107.31%
Basic Shares Outstanding
46.53K 61.93K 259.12K 1.23M
EPS (Diluted)
-2102.2538 -1152.7718 92.0622 -6.7318
EPS (Diluted) Growth
+0.17% +45.16% +107.99% -107.31%
Diluted Shares Outstanding
46.53K 61.93K 259.12K 1.23M
EBITDA
(63.03M) (34.55M) (29.37M) (11.69M)
EBITDA Growth
-13.93% +45.18% +15.01% +60.19%
EBITDA Margin
-73.45% -56.13% -450.87% -144.66%

Redhill Biopharma Ltd. in the News